Loading stock data…
Johnson & Johnson (JNJ)
$263.40+4.13 (+1.59%)
After Hours$263.30-0.10 (-0.04%)· Last close Jul 24
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Johnson & Johnson in the Healthcare sector is trading at $263.40 with a market capitalization of $603.3B. Wall Street consensus targets $270.59 (22 analysts), implying a +2.7% move over the next 12 months. The stock is currently near its 52-week high of $269.43, remaining 18.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $24.06B↓ | $24.56B↑ | $23.99B↑ | $23.74B↑ | $21.89B |
| Gross Profit | $15.96B↓ | $16.60B↓ | $16.69B↑ | $16.11B↑ | $14.54B |
| Operating Income | $6.39B↑ | $5.59B↓ | $7.10B↑ | $6.71B↑ | $6.20B |
| Net Income | $5.24B↑ | $5.12B↓ | $5.15B↓ | $5.54B↓ | $11.00B |
Peer Comparison
UNHPFEABBV
Fundamentals
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative M...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$603.27B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.11
Beta
Defensive asset. Lower volatility than the S&P 500.
0.23
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.99%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.10%
Volume
Today's trading volume
6.35M
Recent News
Johnson & Johnson (JNJ) Reports Early Phase 3 Win In Multiple Myeloma
Johnson & Johnson reported highly positive interim Phase 3 results for the TECVAYLI + TALVEY combination in relapsed or refractory multiple myeloma. The trial was unblinded early after the regimen significantly reduced the risk of disease progression and death. The data are expected to inform future regulatory discussions and potential changes to treatment standards in multiple myeloma. For investors tracking Johnson & Johnson (NYSE:JNJ), this oncology update comes with the stock trading...
How Much Do You Need Invested to Match the Maximum Social Security Benefit With Dividends?
Replacing a Social Security check with dividend income sounds straightforward until you realize the yield you chase changes the capital required by more than a million dollars. The tier you pick carries tradeoffs most income investors only discover after the fact.
Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher
Companies raising guidance, particularly on the earnings front, always deserve some level of attention from investors. Recently, JNJ, GM, and ABT have all raised their outlooks.
This "Boring" Dividend King Is Quietly Turning Into a Growth Machine -- and Many Investors Are Missing It
A name that's often ignored by investors due to its limited historic growth is evolving into a solid income-growth prospect.
J&J's Innovative Medicine Unit Proves Its Resilience in Q2
JNJ's Innovative Medicine unit posts strong Q2 growth despite Stelara's patent loss. See what's fueling momentum into H2 2026.